Efficient nonviral Sleeping Beauty transposon-based TCR gene transfer to peripheral blood lymphocytes confers antigen-specific antitumor reactivity

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Gene Therapy

• Publication date

  2009-06-04

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/gt.2009.54PMID 19494842PMCID PMC3469249
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Redirecting specificity of T-cell populations for CD19 using the Sleeping Beauty system.

  2008cited by this paper
• Adoptive cell transfer: a clinical path to effective cancer immunotherapy

  2008cited by this paper
• Sleeping Beauty transposon-mediated engineering of human primary T cells for therapy of CD19+ lymphoid malignancies.

  2008cited by this paper
• Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells.

  2008cited by this paper
• Adoptive cell transfer therapy.

  2007cited by this paper
• Targeted Sleeping Beauty transposition in human cells.

  2007cited by this paper
• Site-directed transposon integration in human cells

  2007cited by this paper
• Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma.

  2007cited by this paper
• Sustained FVIII expression and phenotypic correction of hemophilia A in neonatal mice using an endothelial-targeted sleeping beauty transposon.

  2006cited by this paper
• A Phase I Study on Adoptive Immunotherapy Using Gene-Modified T Cells for Ovarian Cancer

  2006cited by this paper
• Transposons for gene therapy!

  2006cited by this paper
• Gene Transfer of Tumor-Reactive TCR Confers Both High Avidity and Tumor Reactivity to Nonreactive Peripheral Blood Mononuclear Cells and Tumor-Infiltrating Lymphocytes1

  2006cited by this paper
• High-efficiency transfection of primary human and mouse T lymphocytes using RNA electroporation.

  2006cited by this paper
• Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability.

  2006cited by this paper
• Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes

  2006cited by this paper
• RNA as a source of transposase for Sleeping Beauty-mediated gene insertion and expression in somatic cells and tissues.

  2006cited by this paper
• Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience.

  2006cited by this paper
• High-Resolution Genome-Wide Mapping of Transposon Integration in Mammals

  2005cited by this paper
• Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells.

  2005cited by this paper
• Target-site preferences of Sleeping Beauty transposons.

  2005cited by this paper
• Supernatural T cells: genetic modification of T cells for cancer therapy

  2005cited by this paper
• Recognition of Fresh Human Tumor by Human Peripheral Blood Lymphocytes Transduced with a Bicistronic Retroviral Vector Encoding a Murine Anti-p53 TCR

  2005cited by this paper
• Stable gene transfer and expression in human primary T cells by the Sleeping Beauty transposon system.

  2005cited by this paper
• Transfer of a TCR Gene Derived from a Patient with a Marked Antitumor Response Conveys Highly Active T-Cell Effector Functions

  2005cited by this paper
• Cooperation of human tumor-reactive CD4+ and CD8+ T cells after redirection of their specificity by a high-affinity p53A2.1-specific TCR.

  2005cited by this paper
• Primary Human Lymphocytes Transduced with NY-ESO-1 Antigen-Specific TCR Genes Recognize and Kill Diverse Human Tumor Cell Lines

  2005cited by this paper
• Sleeping beauty transposon-mediated gene therapy for prolonged expression.

  2005cited by this paper
• Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma.

  2005cited by this paper
• Lentivirus Vector-Mediated Expression of Tumor-Associated Epitopes by Human Antigen Presenting Cells

  2004cited by this paper
• Development of hyperactive sleeping beauty transposon vectors by mutational analysis.

  2004cited by this paper
• Mutational Analysis of the N-Terminal DNA-Binding Domain of Sleeping Beauty Transposase: Critical Residues for DNA Binding and Hyperactivity in Mammalian Cells

  2004cited by this paper
• Correction of multi-gene deficiency in vivo using a single 'self-cleaving' 2A peptide–based retroviral vector

  2004cited by this paper
• Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells.

  2003cited by this paper
• Gene transfer into genomes of human cells by the sleeping beauty transposon system.

  2003cited by this paper
• Transcription Start Regions in the Human Genome Are Favored Targets for MLV Integration

  2003cited by this paper
• Human T lymphocytes transduced by lentiviral vectors in the absence of TCR activation maintain an intact immune competence.

  2003cited by this paper
• Lentivirus-Mediated Gene Transfer and Expression in Established Human Tumor Antigen-Specific Cytotoxic T Cells and Primary Unstimulated T Cells

  2003cited by this paper
• Sustainable correction of junctional epidermolysis bullosa via transposon-mediated nonviral gene transfer

  2003cited by this paper
• A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency.

  2003cited by this paper
• High Efficiency TCR Gene Transfer into Primary Human Lymphocytes Affords Avid Recognition of Melanoma Tumor Antigen Glycoprotein 100 and Does Not Alter the Recognition of Autologous Melanoma Antigens

  2003cited by this paper
• Mechanisms That Regulate Silencing of Gene Expression from Retroviral Vectors

  2002cited by this paper
• Silencing of gene expression: implications for design of retrovirus vectors

  2001cited by this paper
• Somatic integration and long-term transgene expression in normal and haemophilic mice using a DNA transposon system

  2000cited by this paper
• The use of anti-CD3 and anti-CD28 monoclonal antibodies to clone and expand human antigen-specific T cells.

  1990cited by this paper

• Genetic Engineering Methods in Primary T Cells

  2025cites this paper
• Advancing human leukocyte antigen-based cancer immunotherapy: from personalized to broad-spectrum strategies for genetically heterogeneous populations.

  2025cites this paper
• Application of adoptive cell therapy in malignant melanoma

  2025cites this paper
• Exploring transposable elements: new horizons in cancer diagnostics and therapeutics

  2025cites this paper
• Novel insights into TCR-T cell therapy in solid neoplasms: optimizing adoptive immunotherapy

  2024cites this paper
• Targeted gene delivery systems for T-cell engineering

  2024cites this paper
• Genome Editing for Engineering the Next Generation of Advanced Immune Cell Therapies.

  2023cites this paper
• Peptide Vaccines in Melanoma: Chemical Approaches towards Improved Immunotherapeutic Efficacy

  2023cites this paper
• T cell immunotherapy for cervical cancer: challenges and opportunities

  2023cites this paper
• Nanomedicine for advanced cancer immunotherapy.

  2022cites this paper
• Adoptive T-cell Immunotherapy: Perfecting Self-Defenses.

  2022cites this paper
• Engineering solutions to design CAR-T cells

  2022cites this paper
• Role of Transposable Elements in Genome Stability: Implications for Health and Disease

  2022cites this paper
• Minicircles for CAR T Cell Production by Sleeping Beauty Transposition: A Technological Overview.

  2022cites this paper
• T Cell Engaging Immunotherapies, Highlighting Chimeric Antigen Receptor (CAR) T Cell Therapy

  2021cites this paper
• Synthetic TILs: Engineered Tumor-Infiltrating Lymphocytes With Improved Therapeutic Potential

  2021cites this paper
• Chimeric Antigen Receptors and Regulatory T Cells: The Potential for HLA-Specific Immunosuppression in Transplantation

  2021cites this paper
• Delivery technologies for T cell gene editing: Applications in cancer immunotherapy

  2021cites this paper
• Potential of transposon-mediated cellular reprogramming towards cell-based therapies

  2020cites this paper
• Breaking Bottlenecks for the TCR Therapy of Cancer

  2020cites this paper
• T-Cell Immunotherapy: From Synthetic Biology to Clinical Practice

  2020cites this paper
• Generation of CAR+ T Lymphocytes Using the Sleeping Beauty Transposon System.

  2020cites this paper
• TCR Redirected T Cells for Cancer Treatment: Achievements, Hurdles, and Goals

  2020cites this paper
• T cell receptor therapy against melanoma—Immunotherapy for the future?

  2020cites this paper
• Latest Advances for the Sleeping Beauty Transposon System: 23 Years of Insomnia but Prettier than Ever

  2020cites this paper
• A highly soluble Sleeping Beauty transposase improves control of gene insertion

  2019cites this paper
• Engineered T Cell Therapy for Cancer in the Clinic

  2019cites this paper
• The determination of gemini surfactants used as gene delivery agents in cellular matrix using validated tandem mass spectrometric method

  2019cites this paper
• Gene editing enables T-cell engineering to redirect antigen specificity for potent tumor rejection

  2019cites this paper
• T-cells "à la CAR-T(e)" - Genetically engineering T-cell response against cancer.

  2019cites this paper
• Gene editing: Towards the third generation of adoptive T-cell transfer therapies

  2019cites this paper
• CAR T Cells Generated Using Sleeping Beauty Transposon Vectors and Expanded with an EBV-Transformed Lymphoblastoid Cell Line Display Antitumor Activity In Vitro and In Vivo

  2019cites this paper
• Gene editing for immune cell therapies

  2019cites this paper
• Cancer immunotherapy with lymphocytes genetically engineered with T cell receptors for solid cancers.

  2019cites this paper
• Adoptive cellular therapies: the current landscape

  2018cites this paper
• Efficient Non-Viral T-Cell Engineering by Sleeping Beauty Minicircles Diminishing DNA Toxicity and miRNAs Silencing the Endogenous T-Cell Receptors

  2018cites this paper
• Principles of adoptive T cell therapy in cancer

  2018cites this paper
• Gene Therapy with the Sleeping Beauty Transposon System.

  2017cites this paper
• Going non-viral: the Sleeping Beauty transposon system breaks on through to the clinical side

  2017cites this paper
• Enhanced CAR T-cell engineering using non-viral Sleeping Beauty transposition from minicircle vectors

  2017cites this paper
• Wide Awake and Ready to Move: 20 Years of Non-Viral Therapeutic Genome Engineering with the Sleeping Beauty Transposon System

  2017cites this paper
• Driving better and safer HER2-specific CARs for cancer therapy

  2017cites this paper
• Retroviral vectors and transposons for stable gene therapy: advances, current challenges and perspectives

  2016cites this paper
• Immunotherapy of acute leukemia by chimeric antigen receptor-modified lymphocytes using an improved Sleeping Beauty transposon platform

  2016cites this paper
• An Efficient Electroporation Protocol for the Genetic Modification of Mammalian Cells

  2016cites this paper
• Stable, Nonviral Expression of Mutated Tumor Neoantigen-specific T-cell Receptors Using the Sleeping Beauty Transposon/Transposase System.

  2016cites this paper
• Minicircle-Based Engineering of Chimeric Antigen Receptor (CAR) T Cells.

  2016cites this paper
• Manufacture of T cells using the Sleeping Beauty system to enforce expression of a CD19-specific chimeric antigen receptor

  2015cites this paper
• Sleeping Beauty transposon system for genetic etiological research and gene therapy of cancers

  2015cites this paper
• Adoptive T-cell therapy in the treatment of viral and opportunistic fungal infections.

  2015cites this paper
• Engineered T cell therapies

  2015cites this paper
• T Cell Immunotherapy: From Synthetic Biology to Clinical Practice

  2015cites this paper
• Isolation of neoantigen-specific T cells from tumor and peripheral lymphocytes.

  2015cites this paper
• The Multiple Faces of Genetically-Modified T Cells : Potential Applications in Therapy

  2014cites this paper
• TCR repertoires of intratumoral T‐cell subsets

  2014cites this paper
• Whole Genome Analyses of a Well-Differentiated Liposarcoma Reveals Novel SYT1 and DDR2 Rearrangements

  2014cites this paper
• Gene Transfer into T Cells

  2014cites this paper
• Adoptive T-Cell Immunotherapy: Perfecting Self-Defenses

  2014cites this paper
• The Tol2 transposon system mediates the genetic engineering of T-cells with CD19-specific chimeric antigen receptors for B-cell malignancies

  2014cites this paper
• Engineering T Cells to Target Tumor Cells

  2014cites this paper
• A new approach to gene therapy using Sleeping Beauty to genetically modify clinical‐grade T cells to target CD19

  2014cites this paper
• An Efficient Low Cost Method for Gene Transfer to T Lymphocytes

  2013cites this paper
• Intracellular delivery of biologically active proteins with peptide-based carriers.

  2013cites this paper
• Faster, cheaper, safer, T-cell engineering.

  2013cites this paper
• Recombinant DNA Technology in Emerging Modalities for Melanoma Immunotherapy

  2013cites this paper
• Sleeping Beauty System to Redirect T-cell Specificity for Human Applications

  2013cites this paper
• Adoptive T-cell Therapy

  2013cites this paper
• How (specific) would you like your T-cells today? Generating T-cell therapeutic function through TCR-gene transfer

  2012cites this paper
• Genetically modulating T-cell function to target cancer.

  2012cites this paper
• A β-sheet structure interacting peptide for intracellular protein delivery into human pluripotent stem cells and their derivatives.

  2012cites this paper
• Retargeting transposon insertions by the adeno-associated virus Rep protein

  2012cites this paper
• Generation of polyfunctional T cells against HCV by T cell redirection and vaccination

  2012cites this paper
• Evaluation of the use of amphipathic peptide-based protein carrier for in vitro cancer research.

  2012cites this paper
• Safety analysis of TCR gene-modified T cells

  2012influential citation
• Combination of Sleeping Beauty transposition and chemically induced dimerization selection for robust production of engineered cells

  2012influential citation
• MART-1- and gp100-expressing and -non-expressing melanoma cells are equally proliferative in tumors and clonogenic in vitro.

  2012cites this paper
• The Sleeping Beauty transposon system for clinical applications

  2012cites this paper
• Nonviral Gene Delivery with the Sleeping Beauty Transposon System

  2011cites this paper
• Mobile genetic elements and cancer. From mutations to gene therapy.

  2011cites this paper
• MOBILE GENETIC ELEMENTS AND CANCER. FROM MUTATIONS TO GENE THERAPY Dedicated to Kyiv and Kyiv region clinical oncologists

  2011cites this paper
• The delivery of biologically active (therapeutic) peptides and proteins into cells.

  2011cites this paper
• T-cell receptor gene therapy: critical parameters for clinical success.

  2011cites this paper
• The hyperactive Sleeping Beauty transposase SB100X improves the genetic modification of T cells to express a chimeric antigen receptor

  2011cites this paper
• The Sleeping Beauty transposon system: a non-viral vector for gene therapy.

  2011cites this paper
• PD-L1 blockade effectively restores strong graft-versus-leukemia effects without graft-versus-host disease after delayed adoptive transfer of T-cell receptor gene-engineered allogeneic CD8+ T cells.

  2011cites this paper
• Combining CD19 redirection and alloanergization to generate tumor-specific human T cells for allogeneic cell therapy of B-cell malignancies.

  2010cites this paper
• Gene transfer efficiency and genome-wide integration profiling of Sleeping Beauty, Tol2, and piggyBac transposons in human primary T cells.

  2010cites this paper
• Intracellular Protein Delivery Systems Formed by Noncovalent Bonding Interactions between Amphipathic Peptide Carriers and Protein Cargos.

  2010cites this paper
• A transposon and transposase system for human application.

  2010cites this paper
• Generation of dual T cell receptor (TCR) T cells by TCR gene transfer for adoptive T cell therapy

  2010cites this paper
• A hybrid lentivirus-transposon vector for safer gene therapy

  2010cites this paper
• Rebalancing Immune Specificity and Function in Cancer by T-Cell Receptor Gene Therapy

  2010cites this paper
• Genetic redirection of T cells for cancer therapy

  2010cites this paper
• NCI First International Workshop on The Biology, Prevention and Treatment of Relapse after Allogeneic Hematopoietic Cell Transplantation: report from the committee on prevention of relapse following allogeneic cell transplantation for hematologic malignancies.

  2010cites this paper
• Enhanced T cell receptor gene therapy for cancer

  2010cites this paper
• The expanding universe of transposon technologies for gene and cell engineering

  2010cites this paper
• Combining CD 19 Redirection and Alloanergization to Generate Tumor-Specific Human T Cells for Allogeneic Cell Therapy of B-Cell Malignancies

  2010cites this paper
• T cell receptor gene therapy for cancer.

  2009cites this paper
• Development of Augmented Leukemia/Lymphoma-Specific T-Cell Immunotherapy for Deployment with Haploidentical Hematopoietic Progenitor-Cell Transplant

  2009cites this paper
• T-cell engineering for cancer immunotherapy.

  2009cites this paper